- Home
- ACDC vs AUPH Comparison
ACDC vs AUPH Comparison
Compare ACDC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACDC
- AUPH
- Stock Information
- Founded
- ACDC 2014
- AUPH 1993
- Country
- ACDC United States
- AUPH Canada
- Employees
- ACDC N/A
- AUPH N/A
- Industry
- ACDC Oilfield Services/Equipment
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ACDC Energy
- AUPH Health Care
- Exchange
- ACDC Nasdaq
- AUPH Nasdaq
- Market Cap
- ACDC 1.1B
- AUPH 1.1B
- IPO Year
- ACDC 2022
- AUPH 1999
- Fundamental
- Price
- ACDC $7.79
- AUPH $8.96
- Analyst Decision
- ACDC Sell
- AUPH Strong Buy
- Analyst Count
- ACDC 4
- AUPH 2
- Target Price
- ACDC $6.50
- AUPH $11.50
- AVG Volume (30 Days)
- ACDC 776.8K
- AUPH 2.0M
- Earning Date
- ACDC 08-07-2025
- AUPH 07-31-2025
- Dividend Yield
- ACDC N/A
- AUPH N/A
- EPS Growth
- ACDC N/A
- AUPH N/A
- EPS
- ACDC N/A
- AUPH 0.27
- Revenue
- ACDC $2,209,700,000.00
- AUPH $247,295,000.00
- Revenue This Year
- ACDC N/A
- AUPH $12.15
- Revenue Next Year
- ACDC $0.38
- AUPH $18.34
- P/E Ratio
- ACDC N/A
- AUPH $33.62
- Revenue Growth
- ACDC N/A
- AUPH 29.20
- 52 Week Low
- ACDC $3.83
- AUPH $5.20
- 52 Week High
- ACDC $10.70
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- ACDC 48.15
- AUPH 63.15
- Support Level
- ACDC $7.58
- AUPH $8.73
- Resistance Level
- ACDC $8.31
- AUPH $9.10
- Average True Range (ATR)
- ACDC 0.62
- AUPH 0.44
- MACD
- ACDC -0.09
- AUPH 0.13
- Stochastic Oscillator
- ACDC 47.76
- AUPH 92.56
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. Its operations are focused in West Texas, East Texas/Louisiana, South Texas, Oklahoma, Uinta, and Appalachian. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.